ArticleFEBS open bio2021

Sorafenib and CuB exert synergistic antitumor effects against hepatocellular carcinoma cells via inhibition of STAT3 phosphorylation.

Xiaoli Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.